macrophage infiltration (P < 0.01 vs vehicle) and -smooth muscle actin expression (P < 0.01 vs vehicle). Gelatin zymography revealed that MMP-2 levels were significantly increased with combination therapy (P < 0.01 vs. vehicle, P < 0.05 vs. MSC or serelaxin alone). In vivo tracing studies showed MSCs homed to the UUO-injured kidney within 1 hour post transplantation where they remained for 36 h. Serelaxin also significantly increased MSC proliferation in vitro (14%; P < 0.05). Conclusions: This study is the first demonstrate that when used in combination, MSCs and the antifibrotic serelaxin, ameliorate pathological fibrosis and improve MSC-mediated repair, in part, via through the up-regulation of MMP-2. Aim: To explore the impact of lead time bias in survival comparisons of preemptive vs non pre-emptive living donor kidney transplants. Background: Pre-emptive and non pre-emptive living kidney donor transplants have similar post-transplant patient survival. However, pre-emptive transplants occur earlier in a patient's disease course and this "lead time" may bias survival comparisons. Methods: Using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, we included adult living donor kidney recipients over 1993-2012 who were transplanted pre-emptively (n = 1237) or after up to 6 months of dialysis (controls, n = 3375). Patients were matched 1:1 by propensity score. Two sources of lead time were added to post-transplant survival times: (1) Dialysis lead time (pre-transplant dialysis duration) and (2) CKD lead time (estimated as the difference in eGFR at commencement of renal replacement therapy (RRT) divided by the assumed rate of CKD progression, with different assumed rates modelled). Survival of pre-emptive and control patients was compared using Cox models. Results: Pre-emptive recipients were more commonly Caucasian, commenced RRT with higher eGFR (median 9.2 vs 6.3 mL/min/1.73 m 2 ) and had fewer co-morbidities. Before matching, pre-emptive transplantation was strongly protective (HR 0.50, 95%CI: 0.39-0.65). After matching there were 539 patients included in each group, and the protective effect was no longer evident (HR 1.17, 95%CI: 0.73-1.87). Adjusting for lead time bias enhanced survival of controls over pre-emptives, although survival was not statistically different across a clinically relevant range of eGFR decline rates. Conclusions: Adjustment for lead time bias neutralises the apparent survival advantage of pre-emptive living donor transplantation. Further studies with larger numbers are needed to confirm this observation. Aim: To present the baseline characteristics of the FAVOURED Trial participants. Background: The FAVOURED Study is an international randomised, doubleblind placebo controlled factorial trial examining whether the use of aspirin and omega-3 fatty acids (fish oil), either alone or in combination, reduces the risk of early failure of de novo arteriovenous (AV) fistula. Methods: Demographic and clinical features of 568 participants enrolled at 35 sites in Australia, New Zealand, Malaysia and United Kingdom are presented. Results: 403 participants from Australia and New Zealand (ANZ), 156 from Malaysia and 9 from United Kingdom. Mean age was 54.8 ± 14.3, 63.5% were males, 52.8% Caucasian and 32.1% Asian. Diabetes was the commonest cause (62.1% in Malaysia and 29.9% in ANZ) although both regions had low prevalence of ischaemic heart disease (4.5% Malaysia vs 8.2% ANZ). Site of the planned fistula differed with 51.9% Malaysian patients having upper-arm AVF compared with 34% in ANZ (P < 0.0001). 60.8% of Malaysians were receiving dialysis (all haemodialysis) compared with 47.4% in ANZ (35.7% utilising HD and the remaining 11.7% with functioning transplant or on PD); P = 0.005. Type of access also differed between regions with 89.2% in Malaysia using non-cuffed catheters and 88.6% of ANZ patients using cuffed catheters. Malaysian patients were relatively more anaemic (Hb 92 vs 112 gm/L; P < 0.0001). Conclusions: A number of regional differences in demographic and clinical characteristics were identified. The FAVOURED trial demonstrates the benefits of multinational collaboration: enabling more effective recruitment and ensuring inclusiveness and diversity of the study subjects resulting in better generalisability of the trial results. were included. Six themes were identified: heightened vulnerability (bodily intrusion, cannulation fears, threat of complications, unpreparedness, dependence on a lifeline, wary of unfamiliar providers); disfigurement (preserving appearance, visual reminder of disease, avoiding stigma); bodily mechanisation (bonded to a machine, internal abnormality, constant maintenance); impinging on way of life (physical incapacitation, instigating family tension, wasting time, added expense); self-preservation and ownership (task-focussed control, advocating for protection, acceptance) and confronting decisions and consequences (imminent dialysis, existential thoughts). Apparent differences across access types were primarily related to complications; clotting, infiltration and stenosis were emphasized with fistula and graft use, whereas infections were a predominant concern in catheter use. Conclusions: Vascular access is more than a surgical intervention; it signifies imminent dialysis, which is emotionally confronting. Patients strive to preserve their access for survival; but simultaneously describe it as an agonizing reminder of their body's failings and "abnormality" of being amalgamated with a machine, disrupting their identity and lifestyle. Timely education and counselling and building patients' trust in providers may improve the quality of dialysis and lead to better outcomes for patients on haemodialysis. Aims: To identify the indications for fistulograms and determine correlation between indication and radiological findings. Background: Dialysis access stenosis is the most common cause of access dysfunction. Clinical monitoring or vascular access surveillance abnormalities prompt a fistulogram. At our institution, fistulogram is primarily used to confirm stenosis. Methods: A retrospective observational study was conducted on 245 fistulograms performed at our institution over a two year period from January 2012 to December 2013. The indication for referral, fistulogram findings, type of fistula and demographic data were obtained. 
BASELINE CHARACTERISTICS OF THE PATIENTS PARTICIPATING IN THE FAVOURED TRIAL
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Aim: To present the baseline characteristics of the FAVOURED Trial participants. Background: The FAVOURED Study is an international randomised, doubleblind placebo controlled factorial trial examining whether the use of aspirin and omega-3 fatty acids (fish oil), either alone or in combination, reduces the risk of early failure of de novo arteriovenous (AV) fistula. Methods: Demographic and clinical features of 568 participants enrolled at 35 sites in Australia, New Zealand, Malaysia and United Kingdom are presented. Results: 403 participants from Australia and New Zealand (ANZ), 156 from Malaysia and 9 from United Kingdom. Mean age was 54.8 ± 14.3, 63.5% were males, 52.8% Caucasian and 32.1% Asian. Diabetes was the commonest cause (62.1% in Malaysia and 29.9% in ANZ) although both regions had low prevalence of ischaemic heart disease (4.5% Malaysia vs 8.2% ANZ). Site of the planned fistula differed with 51.9% Malaysian patients having upper-arm AVF compared with 34% in ANZ (P < 0.0001). 60.8% of Malaysians were receiving dialysis (all haemodialysis) compared with 47.4% in ANZ (35.7% utilising HD and the remaining 11.7% with functioning transplant or on PD); P = 0.005. Type of access also differed between regions with 89.2% in Malaysia using non-cuffed catheters and 88.6% of ANZ patients using cuffed catheters. Malaysian patients were relatively more anaemic (Hb 92 vs 112 gm/L; P < 0.0001). Conclusions: A number of regional differences in demographic and clinical characteristics were identified. The FAVOURED trial demonstrates the benefits of multinational collaboration: enabling more effective recruitment and ensuring inclusiveness and diversity of the study subjects resulting in better generalisability of the trial results. dependence on a lifeline, wary of unfamiliar providers); disfigurement (preserving appearance, visual reminder of disease, avoiding stigma); bodily mechanisation (bonded to a machine, internal abnormality, constant maintenance); impinging on way of life (physical incapacitation, instigating family tension, wasting time, added expense); self-preservation and ownership (task-focussed control, advocating for protection, acceptance) and confronting decisions and consequences (imminent dialysis, existential thoughts). Apparent differences across access types were primarily related to complications; clotting, infiltration and stenosis were emphasized with fistula and graft use, whereas infections were a predominant concern in catheter use. Conclusions: Vascular access is more than a surgical intervention; it signifies imminent dialysis, which is emotionally confronting. Patients strive to preserve their access for survival; but simultaneously describe it as an agonizing reminder of their body's failings and "abnormality" of being amalgamated with a machine, disrupting their identity and lifestyle. Timely education and counselling and building patients' trust in providers may improve the quality of dialysis and lead to better outcomes for patients on haemodialysis. The average age was 57 years, with 35.9% Aboriginal and 28.2% Torres Straight Islander ethnicity. The most common type of vascular access was radiocephalic fistula (49.8%) followed by brachiocephalic fistula (43.3%).
ANYTHING BUT A SIMPLE SURGICAL PROCEDURE: PATIENTS' PERSPECTIVES OF VASCULAR ACCESS FOR HAEMODIALYSIS
INDICATIONS FOR FISTULOGRAPHY AND CORRELATION WITH DETECTION OF ARTERIOVENOUS FISTULA STENOSIS
Further analysis of variables, using bivariate logistic regression analysis, failed to reveal any significant correlation between indications for referral and finding of stenosis. However, increased venous pressure tends to be associated with stenosis (Odds ratio 2.0, 95% CI = 0.84-4.7, P = 0.12).
Both venous hypertension (Odds ratio 0.10, 95% CI = 0.011-1.0, P = 0.052) and development of collaterals (Odds ratio 0.077, 95% CI = 0.0084-0.70, P = 0.023) were associated with negative fistulograms. Conclusions: At our institution, the majority of fistulograms demonstrated access stenosis, based on established referral indications. Both venous hypertension and development of collaterals as referral indications were associated with less likelihood of finding vascular access stenosis in this cohort.
INITIAL EVALUATION OF PLASTIC HAEMODIALYSIS CANNULAE IN AN AUSTRALIAN CENTRE
